Tag Archives: ISCA

Top Bank Stocks To Invest In Right Now

Motilal Oswal’s research report on State Bank of India

SBIN has demonstrated a strong improvement in asset quality, with GNPAs declining by 43% over the past three years, while PCR increased to 68% currently from 40% four years back. Fresh slippages moderated sharply to 1.2% in FY21 (2.5% in 1QFY22), lower v/s many of its private peers. AUCA book stood at INR1.72t – higher than the GNPL pool, with recoveries in the 6-11% range. Over the past five years, the bank has recovered ~INR400b from the AUCA book. We expect the recovery trends to continue as the IBC process gains....More>>>

Top Casino Stocks To Watch For 2019

“Innovation distinguishes between a leader and a follower…” Steve Jobs

This month marks a year-plus since the resignation of Wynn Resorts Ltd. (NASDAQ:WYNN) founder, CEO Steve Wynn. More than any other single executive/entrepreneur in the casino industry, Wynn was widely regarded as sui generis, even by his most ferocious competitors. Was he essentially the indispensable man of his company? Or is one former colleague of mine, clearly a skeptic, correct in quoting Gen. Charles deGaulle – who famously said, “the graveyards are full of indispensable men…”

So when....More>>>

Hot Stocks To Own For 2019

What happened

Shares of Kinross Gold Corporation (NYSE:KGC) fell 14.3% today after the company announced first-quarter 2018 results. While the company delivered top-line growth compared to the year-ago period thanks to higher sales volumes and selling prices, it didn’t trickle down to the bottom line. Instead, net income actually decreased 21% compared to the performance in the first quarter of 2017. It’s the same sticking point Wall Street had with full-year 2017 results.

Turns out, nearly all of the decrease could be explained away by a higher income tax burden.....More>>>

Top 5 Undervalued Stocks To Buy For 2019

Gilead Sciences (GILD) is a large capitalization pharmaceutical and biotechnology company best known for its HIV and HCV (hepatitis C) therapies.

After Gilead showed it could generate large amounts of revenue from new, highly effective cures for HCV, its stock price rose to a peak of $123.57 per share in June 2015. That was quite a climb upward from $37.16 per share at the beginning of 2013, but since then the stock price, although volatile, has drifted mainly downward.

Harvoni pill. Source: Gilead.com

Many analysts and financial journalists, including this author,....More>>>

Best Performing Stocks To Own Right Now

Wells Fargo’s David Maris and team call Valeant Pharmaceutical International’s (VRX) earnings and guidance “worse than feared” and contend that the struggling specialty pharmaceutical company’s “debt problem [is] coming into focus.” They explain:

Reuters

Our preliminary look at 1Q results leads us to believe that Valeant is performing significantly worse than expected. New full-year 2016 adjusted EPS guidance of $6.60-$7.00 falls well below our full-year estimate of $8.81. In many key business areas, Valeant is underperforming consensus…

To....More>>>